Results 81 to 90 of about 85,679 (96)

GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review. [PDF]

Cureus
Buczkowska A, Glinski M, Danieluk J, Adamaszek N, Kacprzak U, Dolega-Mostowska D, Stochaj L, Flejszman M, Wojcik J, Sochowska J.   +9 more
europepmc   +1 more source

Next-Generation GLP-1 Agonist Bioassays: Integrating Precision with Biological Relevance. [PDF]

Int J Mol Sci
Graf C, Reuter J, Rüggeberg S, Mohr S, Petri J, Gelinas S, Niederhaus B, Werner U, Strebe N, Zein ZE, Usener D.   +10 more
europepmc   +1 more source

GLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease. [PDF]

Front Neurosci
Hölscher C.
europepmc   +1 more source

GLP-1-targeted therapies for alcohol and other substance use disorders: a new era on the horizon? [PDF]

J Clin Invest
Leggio L, Simmons WK.
europepmc   +1 more source

Periconceptional GLP-1 Receptor Agonist Exposure: Lower Observed Risk or Lower Certainty? [PDF]

JACC Adv
Singh R, Singh A, Singh AK.
europepmc   +1 more source

Levodopa Efficacy and GLP-1 Receptor Agonists. [PDF]

Mov Disord Clin Pract
Martinez C, Girges C, Foltynie T, Wills AM.   +3 more
europepmc   +1 more source

Patient Experiences With GLP-1 Receptor Agonists.

JAMA Netw Open
de Vere Hunt I, Ramirez-Posada M, Babu CS, Brown-Johnson C, Linos E, Rodriguez F.   +5 more
europepmc   +1 more source

GLP-1 AND CIRRHOSIS: EFFECTS ON MORTALITY AND LIVER-RELATED COMPLICATIONS. [PDF]

Arq Gastroenterol
Onwuzo CN, Elijah OK, Alvina F, Razeq RA, Awuah KB, Onwuzo S.   +5 more
europepmc   +1 more source

Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients. [PDF]

Front Endocrinol (Lausanne)
Lee LA, Tang AF, Asako AE, Ning SF, Reed HA, Duncan E, Lugar HM, Hoekel J, Marshall BA, Hershey T, Urano F.   +10 more
europepmc   +1 more source